Viral kinetic models have proven useful to characterize treatment effectiveness during HCV therapy with interferon (IFN) or with direct-acting antivirals.
Methods
We use a pharmacokinetic/viral kinetic (PK/VK) model to describe HCV RNA kinetics during treatment with danoprevir, a protease inhibitor. In a Phase I study, danoprevir monotherapy was administered for 14 days in ascending doses ranging from 200 to 600 mg per day to 40 patients of whom 32 were treatment-naive and 8 were non-responders to prior pegylated IFN-α/ribavirin treatment.
Results
In all patients, a biphasic decline of HCV RNA during therapy was observed. A two-compartment PK model and a VK model that considered treatment effectiveness to vary with the predicted danoprevir concentration inside the second compartment provided a good fit to the viral load data. A time-varying effectiveness model was also used to fit the viral load data. The antiviral effectiveness increased in a dose-dependent manner, with a 14-day time-averaged effectiveness of 0.95 at the lowest dose (100 mg twice daily) and 0.99 at the highest dose (200 mg three times daily). Prior IFN non-responders exhibited a 14-day time-averaged effectiveness of 0.98 (300 mg twice daily). The second phase decline showed two different behaviours, with 30% of patients exhibiting a rapid decline of HCV RNA, comparable to that seen with other protease inhibitors (>0.3 day-1), whereas the viral decline was slower in the other patients.
Conclusions
Our results are consistent with the modest SVR rates from the INFORM-SVR study where patients were treated with a combination of mericitabine and ritonavir-boosted danoprevir.
References
1.
Mohd HanafiahK., GroegerJ., FlaxmanA.D., WiersmaS.T.Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence.Hepatology2013; 57: 1333–1342.
2.
PearlmanB.L., TraubN.Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.Clin Infect Dis2011; 52: 889–900.
3.
TencateV., SainzB.Jr., CotlerS.J., UprichardS.L.Potential treatment options and future research to increase hepatitis C virus treatment response rate.Hepat Med2010; 2010: 125–145.
4.
CiesekS., von HahnT., MannsM.P.Second-wave protease inhibitors: choosing an heir.Clin Liver Dis2011; 15: 597–609.
5.
ChayamaK., TakahashiS., ToyotaJ.Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.Hepatology2012; 55: 742–748.
6.
McHutchisonJ.G., EversonG.T., GordonS.C.Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.N Engl J Med2009; 360: 1827–1838.
7.
PawlotskyJ-MTreatment of chronic hepatitis C: current and future.Hepatitis C Virus: From Molecular Virology to Antiviral Therapy. City: Springer2013; p. 321–342.
ForestierN., LarreyD., GuyaderD.Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a Phase 1b multiple ascending dose study.J Hepatol2011; 54: 1130–1136.
10.
SeiwertS.D., AndrewsS.W., JiangY.Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).Antimicrob Agents Chemother2008; 52: 4432–4441.
11.
GaneE.J., RobertsS.K., StedmanC.A.Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.Lancet2010; 376: 1467–1475.
12.
ChatterjeeA., GuedjJ., PerelsonA.S.Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?Antivir Ther2012; 17: 1171–1182.
13.
GuedjJ., DahariH., PohlR.T., FerenciP., PerelsonA.S.Understanding silibinin's modes of action against HCV using viral kinetic modeling.J Hepatol2012; 56: 1019–1024.
14.
GuedjJ., DahariH., ShudoE., SmithP., PerelsonA.S.Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128).Hepatology2012; 55: 1030–1037.
15.
GuedjJ., PerelsonA.S.Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration.Hepatology2011; 53: 1801–1808.
16.
AdiwijayaB.S., KiefferT.L., HenshawJ.A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection.PLOS Comput Biol2012; 8: e1002339.
17.
AdiwijayaB.S., HerrmannE., HareB.A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants.PLOS Comput Biol2010; 6: e1000745.
18.
GuedjJ., DahariH., RongL.Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.Proc Natl Acad Sci U S A2013; 110: 3991–3996.
19.
GaneE.J., RouzierR., StedmanC.Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN alpha-2a/RBV in hepatitis C patients.J Hepatol2011; 55: 972–979.
20.
DahariH., LoA., RibeiroR.M., PerelsonA.S.Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy.J Theor Biol2007; 247: 371–381.
21.
SnoeckE., ChanuP., LavielleM.A comprehensive hepatitis C viral kinetic model explaining cure.Clin Pharmacol Ther2010; 87: 706–713.
22.
NeumannA.U., LamN.P., DahariH.Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.Science1998; 282: 103–107.
23.
ShudoE., RibeiroR.M., PerelsonA.S.Modeling HCV kinetics under therapy using PK and PD information.Expert Opin Drug Metab Toxicol2009; 5: 321–332.
24.
ConwayJ.M., PerelsonA.S.A hepatitis C virus infection model with time-varying drug effectiveness: solution and analysis.PLOS Comput Biol2014; 10: e1003769.
25.
SavicR.M., KarlssonM.Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions.AAPS J2009; 11: 558–569.
26.
ZhangL., BealS.L., SheinerL.B.Simultaneous vs. sequential analysis for population PK/PD data I: Best-case performance.J Pharmacokinet Pharmacodyn2003; 30: 387–404.
27.
BurnhamK.P., AndersonD.R.Model selection and multi-model inference: a practical information-theoretic approach. New York: Springer2002.
28.
HolfordN.VPC: the visual predictive check superiority to standard diagnostic (Rorschach) plots.PAGE. 16–17 June 2005, Pamplona, Spain. Abstract 738.
29.
McGivernD.R., MasakiT., WillifordS.Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.Gastroenterology2014; 147: 453–462.
30.
RongL., DahariH., RibeiroR.M., PerelsonA.S.Rapid emergence of protease inhibitor resistance in hepatitis C virus.Sci Trans Med2010; 2: 30ra32.
31.
DixitN.M., Layden-AlmerJ.E., LaydenT.J., PerelsonA.S.Modelling how ribavirin improves interferon response rates in hepatitis C virus infection.Nature2004; 432: 922–924.
32.
AdiwijayaB.S., HareB., CaronP.R.Rapid decrease of wild-type hepatitis C virus on telaprevir treatment.Antivir Ther2009; 14: 591–595.
33.
NguyenT.H., MentréF., LeviM., YuJ., GuedjJ.A pharmacokinetic-viral kinetic model describes the effect of alisporivir monotherapy or in combination with peg-IFN on hepatitis C virologic response.Clin Pharmacol Ther2014; 96: 599–608.
34.
GuedjJ., YuJ., LeviM.Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients.Hepatology2014; 59: 1706–1714.
35.
HerrmannE., ZeuzemS., SarrazinC.Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061.Antivir Ther2006; 11: 371–376.
36.
AdiwijayaB., KiefferT., BartelsD.Modeling, clinical and virology data from Phase 2 and 3 studies support 12- week telaprevir duration in combination with 24- or 48-week peginterferon/ribavirin duration.J Hepatol2011; 54Suppl 1: S160.
37.
LewisH., CunninghamM., FosterG.Second generation direct antivirals and the way to interferon-free regimens in chronic HCV.Best Pract Res Clin Gastroenterol2012; 26: 471–485.
38.
LimS.R., QinX., SusserS.Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution.Antimicrob Agents Chemother2012; 56: 271–279.
39.
RongL., GuedjJ., DahariH.Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model.PLOS Comput Biol2013; 9: e1002959.
40.
KiefferT.L., De MeyerS., BartelsD.J.Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.PLoS ONE2012; 7: e34372.
41.
KuhnE., LavielleM.Maximum likelihood estimation in nonlinear mixed effects models.Comput Stat Data Anal2005; 49: 1020–1038.
42.
GaneE.J., StedmanC.A., HylandR.H.Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.N Engl J Med2013; 368: 34–44.
43.
FeldJ.J., KowdleyK.V., CoakleyE.Treatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin.N Engl J Med2014; 370: 1594–1603.
44.
KowdleyK.V., GordonS.C., ReddyK.R.Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.N Engl J Med2014; 370: 1879–1888.
45.
SulkowskiM.S., GardinerD.F., Rodriguez-TorresM.Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.N Engl J Med2014; 370: 211–221.
46.
GaneE.J., PockrosP.J., ZeuzemS.Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study.Liver Int2015; 35: 79–89.
